MADISON, Wis. , Oct. 3, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the CNNC-Accuray joint venture Tomo ® C radiation therapy system for the Type B market has been approved by the Chinese National Medical Products Administration (NMPA).
MADISON, Wis. , Oct. 2, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has a 510(k) pending for an online adaptive therapy option*, Cenos™, for its Radixact ® System. The solution was unveiled, in partnership with Limbus AI, at the 2023 ASTRO ( American
Accuray develops, manufactures and sells radiation oncology systems that make cancer treatments shorter, safer, smarter and more effective. Accuray provides treatment delivery technologies that set the industry standard for precision and cover the full range of radiation therapy and radiosurgery treatments, as well as fully integrated software solutions that drive faster, smarter treatment planning.